Royalty Report: Drugs, Disease, Cancer – Collection: 266835

License Grant

Licensor, an university grants
—  an exclusive license under the Licensed Patent Rights to manufacture, have manufactured, import, have imported, use, sell, offer for sale, lease or otherwise dispose of Products in the Territory in the Field of Use; and

—  a Co-Exclusive license under the Licensed Patent Rights to manufacture, have manufactured, import, have imported, use, sell, offer for sale, lease or otherwise dispose of Products in the Territory in the Field of Use.

License Property

The patents are for Modified vitamin K-dependent polypeptides.

Vitamin K serves as an essential cofactor for a carboxylase that catalyzes carboxylation of glutamic acid residues on vitamin K-dependent proteins. The key vitamin K-dependent proteins include Coagulation proteins factors II (prothrombin), VII, IX and X. Anticoagulation proteins proteins C, S and Z.

Field of Use

The Fields of Use are
—  Use of Factor VII and/or Factor VIIa, optionally linked to one or more PEG polymers, alone or in combination with other active ingredients for treating or preventing human or animal diseases, with the proviso that any such Factor VII and/or Factor VII a includes at least one mutation in the GLA domain; and,
—  Use of Factor VH and/or Factor VIIa, linked to one or more PEG polymers, alone or in combination with other active ingredients for treating or preventing human or animal diseases, with the proviso that any such Factor VII and/or Factor VIIa includes at least one mutation outside the GLA domain and no mutations in the GLA domain.

License Grant

Licensor grants to the Swiss Licensee a worldwide, exclusive, even as to Licensor, license under the Licensor IP to research, develop, make, have made, use, import, have sold, sell and offer to sell Licensed Products.

License Property

The intellectual property is in respect to Recombinant Factor XIII and related preclinical and clinical studies.

Patent Product means a product that contains Recombinant Factor XIII, the making, using, importation, exportation, offer for sale or sale of which product would infringe, in the absence of the licenses granted under this Agreement, any unexpired Patent Claim.

Recombinant Factor VIIa and rFVIIa mean a protein that has an amino acid sequence of human factor VIIa or its subunits and that is produced by recombinant DNA techniques (including without limitation, production in prokaryotic and eukaryotic host cells and transgenic animals), including variants, derivatives, modifications, fragments, hybrids, mutants, conjugates, fusion proteins and analogs of such protein. Recombinant Factor VIIa and rFVIIa shall mean the active Factor VIIa protein in Licensee’s product known as NovoSeven®.

Recombinant Factor XIII and rFXIII mean a protein that has an amino acid sequence of human factor XIII or its subunits, or any combination thereof, and that is produced by recombinant DNA techniques, including, without limitation, production in prokaryotic and eukaryotic host cells and transgenic animals, including variants, derivatives, modifications, fragments, hybrids, mutants, conjugates, fusion proteins and analogs of such protein.

NovoSeven (coagulation factor viia recombinant) is a vitamin K-dependent glycoprotein consisting of 406 amino acid residues (MW 50 K Dalton). NovoSeven (coagulation factor viia recombinant) is structurally similar to human plasma-derived Factor VIIa.

Field of Use

The field of use is Cancer Treatment or Cardiac Surgery.

Cancer Treatment Indication means bleeding in a patient with malignancy that occurs either as a consequence of the malignancy or the treatment of the malignancy and requires medical intervention.

Cardiac Surgery Indication means bleeding or oozing of blood in a patient undergoing cardiac surgery or having undergone cardiac surgery that occurs during or following the surgery and requires medical intervention.

NovoSeven® RT (Coagulation Factor VIIa [Recombinant]) is used for
– Treatment of bleeding and prevention of bleeding for surgeries and procedures in adults and children with hemophilia A or B with inhibitors, congenital Factor VII (FVII) deficiency, and people with Glanzmann’s thrombasthenia who have a decreased or absent response to platelet transfusions
– Treatment of bleeding and prevention of bleeding for surgeries and procedures in adults with acquired hemophilia

License Grant

The University grants, to the extent of the Licensed Territory, a non-exclusive right and license to use University Technology in the Licensed Field, with the right to sublicense, provided that each such sublicense is granted concurrently with the grant of a license to Patent Rights, if any.

The University grants, to the extent of the Licensed Territory, an exclusive license under the Patent Rights to make, have made, use, offer for sale, sell and import Licensed Products in the Licensed Field, with the right to sublicense.

License Property

The University owns and controls valuable inventions known as Identification of the gene for vitamin K epoxide reduclase, Production of a peptide useful for the isolation of the vitamin-K carboxylase and, Human factor IX variants with an extended half life, collectively the inventions.

Field of Use

The Licensed Field means, and is limited to, the practice of the Inventions for the production of Factors IX and VII including without limitation all cleavage products and mutants thereof, for therapeutic use.

Licensee focuses on providing novel oncology and hematology therapeutics.